Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2005.065599v1, 2006; 10.1373/clinchem.2005.065599
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.065599v1
52/6/1070    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holzscheiter, L.
Right arrow Articles by Magdolen, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holzscheiter, L.
Right arrow Articles by Magdolen, V.

Received on December 20, 2005
Accepted on March 24, 2006

Cancer Diagnostics

Quantitative Reverse Transcription-PCR Assay for Detection of mRNA Encoding Full-Length Human Tissue Kallikrein 7: Prognostic Relevance of KLK7 mRNA Expression in Breast Cancer{dagger}

Leon Holzscheiter 1, Julia C. Biermann 1, Matthias Kotzsch 2, Panagiotis Skoufalis 3, Juliane Farthmann 1, Gustavo Baretton 2, Thomas Luther 4, Vivianne C.G. Tjan-Heijnen 5, Maroulio Talieri 3, Manfred Schmitt 1, Fred C.G.J. Sweep 6, Paul N. Span 6, Viktor Magdolen 1*

1 Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
2 Institute of Pathology, Technical University of Dresden, Dresden, Germany
3 G Papanicolaou Research Center-Saint Savas Hospital, Athens, Greece
4 Institute of Pathology, Technical University of Dresden, Dresden, Germany, and Medical Laboratory Unit, Bautzen, Germany
5 Medical Oncology
6 Chemical Endocrinology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

* To whom correspondence should be addressed. E-mail: viktor.magdolen{at}lrz.tum.de.

Background: The human tissue kallikrein gene family (KLK1 to KLK15) encodes a group of 15 serine proteases (hK1 to hK15), several of which have been implicated in cancer-related processes.

Methods: We established a specific quantitative reverse transcription-PCR assay for full-length KLK7 mRNA that excluded amplification of the exon 2 deletion splice variant (the latter does not encode a functional protease), and evaluated full-length KLK7 mRNA expression [normalized to human glucose-6-phosphate dehydrogenase (h-G6PDH)] in tumor tissue specimens from 155 breast cancer patients.

Results: High KLK7 mRNA expression (continuous) was significantly associated with a better patient outcome according to both univariate (P = 0.005) and multivariate (P = 0.046) Cox survival analysis. Separation of patients by optimized dichotomization revealed a significantly better prognosis patients with high KLK7 mRNA status (n = 89) compared with patients with low KLK7 mRNA status [n = 66; univariate hazard ratio (HR) = 0.45 (P = 0.001); multivariate HR = 0.50 (P = 0.005)]. In the subgroup of patients not receiving adjuvant treatment (n = 69), KLK7 mRNA status was a significant prognosticator [univariate HR = 0.29 (P = 0.002); multivariate HR = 0.40 (P = 0.034)]. This subgroup was least influenced by postoperative treatment and thus best showed the impact of KLK7 expression on the natural course of breast cancer disease.

Conclusion: Expression of full-length KLK7 mRNA may represent a new prognostic marker in breast cancer disease.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.